Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …

The aim of candidate universal influenza vaccines is to provide broad protection against
influenza A and B viruses. Studies have demonstrated that broadly reactive antibodies …

Each severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant renews
concerns about decreased vaccine neutralization weakening efficacy. However, while …

Antibodies play a critical role in protection against influenza; yet titers and viral neutralization
represent incomplete correlates of immunity. Instead, the ability of antibodies to leverage the …

The pandemic COVID-19 has spread widely throughout the globe and has been responsible
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …

Highlights•Broadly neutralizing antibodies against influenza A and B represents a safe and
affordable alternative to convalescent plasma.•The large majority of broadly neutralizing …

IgA is the second most abundant antibody present in circulation and is enriched at mucosal
surfaces. As such, IgA plays a key role in protection against a variety of mucosal pathogens …

We review the phenomenon of “original antigenic sin”(OAS) in antibody responses to
influenza A virus (IAV) infection or vaccination. OAS refers to the preferential induction of …

Influenza A virus (IAV) imposes a significant socioeconomic burden on humanity.
Vaccination is effective in only 60% of individuals, even under optimal circumstances. The …

A substantial proportion of influenza-related childhood deaths are due to infection with
influenza B viruses, which co-circulate in the human population as two antigenically distinct …